The troubled drug giant AstraZeneca, which is overhauling its research operations, is betting at least $240 million that a novel but untested technology from a small biotechnology company can provide it with a huge array of new drugs. Technology developed by Derrick J. Rossi, assistant professor of stem cell and regenerative biology at FAS, is cited.
